Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea

Angiology

Volumn 63, Issue 8, 2012, Pages 617-621

  Sopkova, Zuzana ^a   Berneis, Kaspar ^b,c   Rizzo, Manfredi ^d,e   Spinas, Giatgen A ^b   Dorkova, Zuzana ^a   Tisko, Radovan ^a   Tkacova, Ruzena ^a  

^a L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY OF PALERMO   (Italy)

^e Euro Mediterranean Institute of Science and Technology   (Italy)

Author keywords

atherosclerosis; dense low density lipoprotein; low density lipoprotein size; metabolic syndrome; obstructive sleep apnea; small

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; BLOOD OXYGEN TENSION; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; GEL ELECTROPHORESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PARTICLE SIZE; POLYSOMNOGRAPHY; SLEEP DISORDERED BREATHING; TRIACYLGLYCEROL BLOOD LEVEL;

CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; HUMANS; LINEAR MODELS; LIPOPROTEINS, LDL; METABOLIC SYNDROME X; POLYSOMNOGRAPHY; SLEEP APNEA, OBSTRUCTIVE;

EID: 84870685189     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711433811     Document Type: Article

References (27)

1. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005 ; 365 (9464). 1046-1053
2. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000 ; 342 (19). 1378-1384
3. Coughlin SR, Mawdsley L, Mugarza JA, et al. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J. 2007 ; 29 (4). 720-727
4. Lavie L. Oxidative stress-A unifying paradigm in obstructive sleep apnea and comorbidities. Prog Cardiovasc Dis. 2009 ; 51 (4). 303-312
5. Drager LF, Bortolotto LA, Lorenzi MC, et al. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2005 ; 172 (5). 613-618
6. Drager LF, Jun J, Polotsky VY. Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis. Curr Opin Endocrinol Diabetes Obes. 2010 ; 17 (2). 161-165
7. Rizzo M, Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment. QJM Int J Med. 2006 ; 99 (1). 1-14
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 ; 106 (25). 3143-3421
9. Gazi I, Tsimihodimos V, Filippatos T, et al. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism. 2006 ; 55 (7). 885-891
10. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ; 120 (16). 1640-1645
11. Rechtschaffen A, Kales A A Manual of Standardized Terminology: Techniques and Scoring Stages of Human Subjects. Los Angeles, CA: UCLA Brain Information Service/Brain Research Institute ; 1968 :
12. Krauss R, Burke D. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982 ; 23 (1). 97-104
13. Rizzo M, Pernice V, Frasheri A, et al. Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol. 2009 ; 70 (6). 870-875
14. St Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005 ; 25 (3). 553-559
15. Punjabi NM, Polotsky VY. Disorders of glucose metabolism in sleep apnea. J Appl Physiol. 2005 ; 99 (5). 1998-2007
16. Lam JC, Lam B, Lam CL, et al. Obstructive sleep apnea and the metabolic syndrome in community/based Chinese adults in Hong Kong. Respir Med. 2006 ; 100 (6). 980-987
17. Drager LF, Lopes HF, Maki-Nunes C, et al. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One. 2010 ; 5 (8). e12065
18. Can M, Acikgoz S, Bayraktaroglu T, et al. Serum cardiovascular risk factors in obstructive sleep apnea. Chest. 2006 ; 129 (2). 233-237
19. Li J, Savransky V, Nanayakkara A, et al. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J Appl Physiol. 2007 ; 102 (2). 557-563
20. Savransky V, Nanayakkara A, Li J, et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med. 2007 ; 175 (12). 1290-1297
21. Rizzo M, Kotur-Stevuljevic J, Berneis K, et al. Atherogenic dyslipidemia and oxidative stress: a new look. Transl Res. 2009 ; 153 (5). 217-223
22. Rizzo M, Berneis K, Koulouris S, et al. Should we measure routinely oxidized and small dense low-density lipoproteins in subjects with type 2 diabetes?. Int J Clin Pract. 2010 ; 64 (12). 1632-1642
23. Tkacova R, Rizzo M, Berneis K. Therapy with non-invasive ventilation in patients with obstructive sleep apnoea: effects on atherogenic lipoprotein phenotype. Med Hypotheses. 2009 ; 73 (3). 441-444
24. Rizzo M, Mikhailidis DP. Editorial: there is more to predicting vascular disease than just established risk factors. Curr Pharm Des. 2011 ; 17 (33). 3608-3610
25. Rizzo M, Rizvi AA, Rini GB, Berneis K. The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?. Acta Diabetol. 2009 ; 46 (1). 1-11
26. Mikhailidis DP, Elisaf MS, Rizzo M, et al. "European Panel on Low Density Lipoprotein (LDL) Subclasses": A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011 ; 9 (5). 533-571
27. Mikhailidis DP, Elisaf MS, Rizzo M, et al. "European Panel on Low Density Lipoprotein (LDL) Subclasses": A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011 ; 9 (5). 531-532